<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Repatha® (evolocumab) - Comprehensive Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 50%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(35deg);
        }

        .drug-title {
            position: relative;
            z-index: 1;
        }

        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
        }

        .drug-subtitle {
            font-size: 24px;
            opacity: 0.9;
            margin-bottom: 5px;
        }

        .drug-company {
            font-size: 18px;
            opacity: 0.8;
        }

        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e9ecef;
            padding: 0;
            overflow-x: auto;
        }

        .nav-tab {
            padding: 20px 30px;
            cursor: pointer;
            border: none;
            background: none;
            font-size: 16px;
            font-weight: 500;
            color: #6c757d;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }

        .nav-tab:hover {
            color: #667eea;
            background: rgba(102, 126, 234, 0.05);
        }

        .nav-tab.active {
            color: #667eea;
            background: white;
        }

        .nav-tab.active::after {
            content: '';
            position: absolute;
            bottom: -2px;
            left: 0;
            right: 0;
            height: 3px;
            background: #667eea;
        }

        .content {
            padding: 40px;
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .section {
            margin-bottom: 40px;
        }

        .section-title {
            font-size: 28px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 3px solid #667eea;
        }

        .mechanism-card {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }

        .mechanism-title {
            font-size: 22px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 15px;
        }

        .mechanism-content {
            color: #5a6c7d;
            line-height: 1.8;
            font-size: 16px;
        }

        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .dosing-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.2);
            border-color: #667eea;
        }

        .dosing-label {
            font-size: 14px;
            color: #6c757d;
            margin-bottom: 10px;
        }

        .dosing-value {
            font-size: 28px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .dosing-detail {
            font-size: 14px;
            color: #5a6c7d;
        }

        .timeline-container {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }

        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            transform: translateX(-50%);
        }

        .timeline-item {
            position: relative;
            margin: 30px 0;
            display: flex;
            align-items: center;
        }

        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }

        .timeline-content {
            width: 45%;
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
            cursor: pointer;
        }

        .timeline-content:hover {
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.3);
            border-color: #667eea;
        }

        .timeline-date {
            font-size: 18px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 8px;
        }

        .timeline-description {
            font-size: 14px;
            color: #6c757d;
            line-height: 1.6;
        }

        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: white;
            border: 4px solid #667eea;
            border-radius: 50%;
            z-index: 2;
        }

        .timeline-tooltip {
            position: absolute;
            background: #2c3e50;
            color: white;
            padding: 15px;
            border-radius: 8px;
            font-size: 14px;
            width: 300px;
            opacity: 0;
            pointer-events: none;
            transition: opacity 0.3s;
            z-index: 1000;
            box-shadow: 0 10px 30px rgba(0,0,0,0.3);
        }

        .timeline-content:hover .timeline-tooltip {
            opacity: 1;
        }

        .trials-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin-top: 20px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            border-radius: 12px;
            overflow: hidden;
        }

        .trials-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }

        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .trials-table tbody tr {
            border-bottom: 1px solid #e9ecef;
            transition: all 0.3s;
        }

        .trials-table tbody tr:hover {
            background: rgba(102, 126, 234, 0.05);
            transform: translateX(5px);
        }

        .trials-table td {
            padding: 15px;
            font-size: 14px;
            color: #5a6c7d;
        }

        .trial-name {
            font-weight: 600;
            color: #2c3e50;
        }

        .trial-phase {
            display: inline-block;
            padding: 4px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            background: #e9ecef;
            color: #6c757d;
        }

        .trial-phase.phase3 {
            background: #d4edda;
            color: #155724;
        }

        .outcome-chart {
            margin: 30px 0;
            padding: 20px;
            background: #f8f9fa;
            border-radius: 12px;
        }

        .chart-container {
            position: relative;
            height: 400px;
            margin-top: 20px;
        }

        .efficacy-bar-chart {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 300px;
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            margin: 0 10px;
        }

        .bar {
            width: 60px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 8px 8px 0 0;
            transition: all 0.3s;
            position: relative;
            margin-bottom: 10px;
        }

        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(102, 126, 234, 0.4);
        }

        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            color: #667eea;
            font-size: 18px;
        }

        .bar-label {
            text-align: center;
            font-size: 12px;
            color: #6c757d;
            margin-top: 10px;
            max-width: 100px;
        }

        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .safety-card {
            background: white;
            border: 1px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }

        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }

        .safety-title {
            font-size: 18px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }

        .safety-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            margin-right: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
        }

        .safety-content {
            color: #6c757d;
            line-height: 1.8;
        }

        .safety-list {
            list-style: none;
            margin-top: 10px;
        }

        .safety-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f1f3f5;
            display: flex;
            justify-content: space-between;
        }

        .safety-list li:last-child {
            border-bottom: none;
        }

        .percentage {
            font-weight: 600;
            color: #667eea;
        }

        .market-timeline {
            position: relative;
            padding: 30px 0;
        }

        .market-event {
            background: white;
            border-left: 4px solid #667eea;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 12px 12px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
        }

        .market-event:hover {
            transform: translateX(10px);
            box-shadow: 0 10px 30px rgba(102, 126, 234, 0.2);
        }

        .market-year {
            font-size: 20px;
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }

        .market-description {
            color: #5a6c7d;
            line-height: 1.6;
        }

        .price-tag {
            display: inline-block;
            background: #ffeaa7;
            color: #2d3436;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .competition-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .competitor-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .competitor-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
            border-color: #667eea;
        }

        .competitor-name {
            font-size: 18px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .competitor-detail {
            font-size: 14px;
            color: #6c757d;
            margin: 5px 0;
        }

        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 10px auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">Repatha® (evolocumab)</div>
                <div class="drug-subtitle">PCSK9 Monoclonal Antibody</div>
                <div class="drug-company">Amgen • FDA/EMA Approved 2015</div>
            </div>
        </div>

        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('market')">Market & Commercial</button>
        </div>

        <div class="content">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="section">
                    <h2 class="section-title">Mechanism of Action</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">PCSK9 Inhibition via Monoclonal Antibody</div>
                        <div class="mechanism-content">
                            Repatha is a fully human monoclonal antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream. By inhibiting PCSK9's interaction with LDL receptors (LDL-R) on hepatocytes, it prevents receptor degradation, leading to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li style="margin: 8px 0;">Increased LDL-R recycling on liver surface</li>
                                <li style="margin: 8px 0;">Enhanced clearance of LDL cholesterol from blood</li>
                                <li style="margin: 8px 0;">Substantial reductions in circulating LDL-C levels (50-70%)</li>
                                <li style="margin: 8px 0;">Rapid onset of effect (peak reduction within 1-2 weeks)</li>
                            </ul>
                            <div style="margin-top: 20px; padding: 15px; background: rgba(102, 126, 234, 0.1); border-radius: 8px;">
                                <strong>Key Differentiators:</strong> Unlike statins (which upregulate LDL-R expression) or inclisiran (which silences PCSK9 gene via siRNA), evolocumab acts post-translationally on circulating PCSK9, providing immediate effect without genetic modification.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Dosing & Administration</h2>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Standard Dose</div>
                            <div class="dosing-value">140 mg</div>
                            <div class="dosing-detail">Every 2 weeks (Q2W)<br>OR<br>420 mg monthly</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value">12-26</div>
                            <div class="dosing-detail">Subcutaneous self-injection after training</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HoFH Patients</div>
                            <div class="dosing-value">420 mg</div>
                            <div class="dosing-detail">Monthly, can increase to Q2W after 12 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Administration Sites</div>
                            <div class="dosing-value">3 Sites</div>
                            <div class="dosing-detail">Abdomen, thigh, or upper arm</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Patient Populations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Approved Indications</div>
                        <div class="mechanism-content">
                            <strong>Adults:</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>Heterozygous Familial Hypercholesterolemia (HeFH)</li>
                                <li>Homozygous Familial Hypercholesterolemia (HoFH)</li>
                                <li>Clinical ASCVD requiring additional LDL-C lowering</li>
                                <li>CV risk reduction (MI, stroke, coronary revascularization)</li>
                            </ul>
                            <strong>Pediatric (Age 10+):</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>HeFH or HoFH patients</li>
                            </ul>
                            <div style="margin-top: 15px; padding: 10px; background: #fff3cd; border-radius: 5px;">
                                <strong>Note:</strong> No dose adjustments required for renal/hepatic impairment, age, or weight
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="section">
                    <h2 class="section-title">FDA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">August 27, 2015</div>
                                <div class="timeline-title">Initial FDA Approval</div>
                                <div class="timeline-description">
                                    Approved for HeFH, clinical ASCVD, and HoFH in adults/adolescents 13+. Second PCSK9 inhibitor approved in US.
                                </div>
                                <div class="timeline-tooltip">
                                    Adjunct to diet and maximally tolerated statin therapy. No CRLs or safety delays during review.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 11, 2016</div>
                                <div class="timeline-title">Pushtronex System Approval</div>
                                <div class="timeline-description">
                                    First single monthly injection device for 420 mg dosing (on-body infusor).
                                </div>
                                <div class="timeline-tooltip">
                                    Automated delivery system, though later discontinued in some markets due to patient experience issues.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">December 1, 2017</div>
                                <div class="timeline-title">CV Outcomes Indication</div>
                                <div class="timeline-description">
                                    First PCSK9 inhibitor with outcomes-based indication for MI, stroke, and revascularization reduction.
                                </div>
                                <div class="timeline-tooltip">
                                    Based on FOURIER trial data showing 15% MACE reduction in established CVD patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">February 2021</div>
                                <div class="timeline-title">Pediatric Expansion</div>
                                <div class="timeline-description">
                                    Age limit lowered from 13+ to 10+ years for HeFH/HoFH patients.
                                </div>
                                <div class="timeline-tooltip">
                                    Based on HAUSER-RCT pediatric trial showing safety and efficacy in younger patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2024</div>
                                <div class="timeline-title">Label Updates</div>
                                <div class="timeline-description">
                                    Pregnancy/lactation data added from post-marketing reports.
                                </div>
                                <div class="timeline-tooltip">
                                    Insufficient evidence of fetal harm but discontinuation advised during pregnancy. No new safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>

                    <h2 class="section-title">EMA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">July 17, 2015</div>
                                <div class="timeline-title">EMA Marketing Authorization</div>
                                <div class="timeline-description">
                                    Approved for primary hypercholesterolemia and mixed dyslipidemia. Included statin-intolerant patients.
                                </div>
                                <div class="timeline-tooltip">
                                    Broader initial indication than FDA, predated US approval by one month.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">February 21, 2017</div>
                                <div class="timeline-title">Automated Mini-Doser</div>
                                <div class="timeline-description">
                                    420 mg single-dose delivery option approved for European market.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May 16, 2018</div>
                                <div class="timeline-title">CV Risk Reduction</div>
                                <div class="timeline-description">
                                    Expanded indication for MI, stroke, and PAD risk reduction based on FOURIER.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">June 28, 2024</div>
                                <div class="timeline-title">Latest Revision</div>
                                <div class="timeline-description">
                                    Updated SmPC, labeling, and package leaflet. No major safety changes.
                                </div>
                                <div class="timeline-tooltip">
                                    Continuous monitoring via PBRERs. Pricing disputes in France but no safety-related restrictions.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Clinical Development Program</h2>
                    
                    <table class="trials-table">
                        <thead>
                            <tr>
                                <th>Trial Name</th>
                                <th>Phase</th>
                                <th>N</th>
                                <th>Year</th>
                                <th>Primary Endpoint</th>
                                <th>Key Results</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="trial-name">MENDEL</td>
                                <td><span class="trial-phase">Phase 2</span></td>
                                <td>406</td>
                                <td>2013</td>
                                <td>% LDL-C change at week 12</td>
                                <td>39-53% reduction vs placebo/ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">GAUSS</td>
                                <td><span class="trial-phase">Phase 2</span></td>
                                <td>160</td>
                                <td>2013</td>
                                <td>% LDL-C change (statin-intolerant)</td>
                                <td>Similar efficacy in statin-intolerant patients</td>
                            </tr>
                            <tr>
                                <td class="trial-name">LAPLACE-2</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,896</td>
                                <td>2014</td>
                                <td>% LDL-C change at weeks 10-12</td>
                                <td>63-75% reduction vs placebo</td>
                            </tr>
                            <tr>
                                <td class="trial-name">DESCARTES</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>901</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 52</td>
                                <td>57% sustained reduction</td>
                            </tr>
                            <tr>
                                <td class="trial-name">RUTHERFORD-2</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>331</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 12 (HeFH)</td>
                                <td>~60% reduction in HeFH patients</td>
                            </tr>
                            <tr>
                                <td class="trial-name">TESLA/TAUSSIG</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>106</td>
                                <td>2015</td>
                                <td>LDL-C reduction (HoFH)</td>
                                <td>31% reduction in HoFH</td>
                            </tr>
                            <tr style="background: rgba(102, 126, 234, 0.05);">
                                <td class="trial-name"><strong>FOURIER</strong></td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td><strong>27,564</strong></td>
                                <td><strong>2017</strong></td>
                                <td><strong>CV death, MI, stroke, UA, revasc</strong></td>
                                <td><strong>HR 0.85 (15% RRR), p<0.001</strong></td>
                            </tr>
                            <tr>
                                <td class="trial-name">EBBINGHAUS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,974</td>
                                <td>2017</td>
                                <td>Cognitive function</td>
                                <td>No cognitive impairment vs placebo</td>
                            </tr>
                            <tr>
                                <td class="trial-name">EVOPACS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>308</td>
                                <td>2019</td>
                                <td>% LDL-C change at week 8 (ACS)</td>
                                <td>77% reduction, safe in-hospital start</td>
                            </tr>
                            <tr>
                                <td class="trial-name">FOURIER-OLE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>6,635</td>
                                <td>2022</td>
                                <td>Long-term MACE (up to 8.6 years)</td>
                                <td>15% RRR sustained, low AE rates</td>
                            </tr>
                            <tr>
                                <td class="trial-name">EVOLVE-MI</td>
                                <td><span class="trial-phase">Phase 4</span></td>
                                <td>Ongoing</td>
                                <td>2022-</td>
                                <td>MACE post-MI</td>
                                <td>Interim: Feasible early initiation</td>
                            </tr>
                            <tr>
                                <td class="trial-name">VESALIUS-CV</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>TBD</td>
                                <td>2026</td>
                                <td>Primary prevention MACE</td>
                                <td>Results pending</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Efficacy Outcomes</h2>
                    <div class="efficacy-bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 60%;">
                                <span class="bar-value">60%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(Average)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 59%; background: linear-gradient(180deg, #48dbfb 0%, #0984e3 100%);">
                                <span class="bar-value">59%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 30%; background: linear-gradient(180deg, #fdcb6e 0%, #e17055 100%);">
                                <span class="bar-value">30 mg/dL</span>
                            </div>
                            <div class="bar-label">Median LDL<br>Achieved</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 20%; background: linear-gradient(180deg, #a29bfe 0%, #6c5ce7 100%);">
                                <span class="bar-value">20%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 15%; background: linear-gradient(180deg, #55efc4 0%, #00b894 100%);">
                                <span class="bar-value">15%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(Long-term)</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">FOURIER Trial - Detailed Outcomes</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Primary & Secondary Endpoints</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 20px;">
                                <div>
                                    <strong>Primary Composite (MACE-5):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, MI, stroke, UA hospitalization, coronary revascularization</li>
                                        <li><strong>HR 0.85 (95% CI: 0.79-0.92)</strong></li>
                                        <li><strong>20% relative risk reduction, p<0.001</strong></li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Key Secondary (MACE-3):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, MI, stroke</li>
                                        <li><strong>HR 0.80 (95% CI: 0.73-0.88)</strong></li>
                                        <li><strong>20% relative risk reduction</strong></li>
                                    </ul>
                                </div>
                            </div>
                            <div style="margin-top: 20px; padding: 15px; background: #fff3cd; border-radius: 8px;">
                                <strong>Note on Mortality:</strong> No significant reduction in CV death (HR 1.05) or all-cause mortality (HR 1.04), likely due to short median follow-up of 2.2 years. Longer follow-up in FOURIER-OLE showed trend toward mortality benefit.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Safety Profile Overview</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Cumulative Exposure:</strong> ~2.5 million patient-years as of May 2024<br>
                            <strong>Black Box Warnings:</strong> None<br>
                            <strong>Major Safety Signals:</strong> None identified<br>
                            <strong>Discontinuation Rate:</strong> ~1.6% due to adverse events
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Common Adverse Events</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">1</div>
                                Most Common AEs
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Nasopharyngitis <span class="percentage">10.5%</span></li>
                                    <li>Upper respiratory infection <span class="percentage">9.3%</span></li>
                                    <li>Influenza <span class="percentage">7.5%</span></li>
                                    <li>Back pain <span class="percentage">6.2%</span></li>
                                    <li>Injection site reactions <span class="percentage">5.7%</span></li>
                                    <li>Myalgia <span class="percentage">5.4%</span></li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">2</div>
                                Injection Site Reactions
                            </div>
                            <div class="safety-content">
                                Overall incidence: 5.7%
                                <ul class="safety-list">
                                    <li>Erythema <span class="percentage">2.1%</span></li>
                                    <li>Pain <span class="percentage">1.8%</span></li>
                                    <li>Bruising <span class="percentage">1.2%</span></li>
                                </ul>
                                Generally mild and transient
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">3</div>
                                Serious Adverse Events
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Overall SAEs <span class="percentage">2.4%</span></li>
                                    <li>Similar to placebo <span class="percentage">2.3%</span></li>
                                    <li>Hypersensitivity (rare) <span class="percentage"><1%</span></li>
                                    <li>Anaphylaxis <span class="percentage">Very rare</span></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Neurocognitive Safety</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">EBBINGHAUS Study Results</div>
                        <div class="mechanism-content">
                            <strong>Primary Finding:</strong> No impact on cognitive function despite very low LDL-C levels<br><br>
                            
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Cognitive Domains Tested:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Executive function</li>
                                        <li>Working memory</li>
                                        <li>Memory function</li>
                                        <li>Psychomotor speed</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Results:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Neurocognitive AEs: 1.6% vs 1.5% placebo</li>
                                        <li>No correlation with LDL level</li>
                                        <li>No difference in any cognitive domain</li>
                                        <li>8+ year follow-up confirms safety</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>2024 Update:</strong> Study of 3,000+ patients with very low LDL (<20 mg/dL) showed no cognitive association over 5+ years. Meta-analyses confirm no neurocognitive risk.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Special Populations & Monitoring</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">P</div>
                                Pregnancy & Lactation
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• Insufficient evidence of fetal harm</li>
                                    <li>• Discontinuation advised during pregnancy</li>
                                    <li>• Limited data on breastfeeding</li>
                                    <li>• 2024 label update with post-marketing data</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">I</div>
                                Immunogenicity
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• Binding antibodies: 0.3%</li>
                                    <li>• Neutralizing antibodies: Rare</li>
                                    <li>• No impact on efficacy</li>
                                    <li>• No cross-reactivity concerns</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">D</div>
                                Diabetes Risk
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• New-onset diabetes: HR 1.05</li>
                                    <li>• Not statistically significant</li>
                                    <li>• Safe in T1D patients (2025 data)</li>
                                    <li>• No glucose monitoring required</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div id="market" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Pricing Evolution</h2>
                    <div class="market-timeline">
                        <div class="market-event">
                            <div class="market-year">2015</div>
                            <div class="market-description">
                                <span class="price-tag">US: $14,000-14,600/year</span>
                                <span class="price-tag">EU: ~$6,780/year</span><br>
                                Launch pricing led to significant payer pushback and strict prior authorizations
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2018</div>
                            <div class="market-description">
                                <span class="price-tag">60% price cut to $5,850/year</span><br>
                                Post-FOURIER price reduction to improve access. Net price ~$4,500 with rebates
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2020</div>
                            <div class="market-description">
                                Only 3% of eligible high-risk ASCVD patients receiving therapy due to access barriers
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2025</div>
                            <div class="market-description">
                                <span class="price-tag">Annual sales: ~$1.3 billion</span><br>
                                Sales plateaued. France pricing disputes. Biosimilars approaching in 2028
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Access Challenges</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Prior Authorization Requirements:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>~80% initial denial rate in US</li>
                                <li>Must prove statin failure/intolerance</li>
                                <li>LDL threshold requirements (>100-130 mg/dL)</li>
                                <li>Documentation of CV risk factors</li>
                                <li>Step therapy through other lipid agents</li>
                            </ul>
                            
                            <strong>Payer Restrictions:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Express Scripts/UnitedHealth: Strict step therapy protocols</li>
                                <li>VA/CMS: Negotiated discounts but limited to severe cases</li>
                                <li>NICE/HTA: Only for LDL >3.5-5 mmol/L in high-risk (ICER >£30,000/QALY)</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Competitive Landscape</h2>
                    <div class="competition-grid">
                        <div class="competitor-card">
                            <div class="competitor-name">Praluent (alirocumab)</div>
                            <div class="competitor-detail">PCSK9 mAb - Sanofi/Regeneron</div>
                            <div class="competitor-detail">Similar efficacy, first to market</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Leqvio (inclisiran)</div>
                            <div class="competitor-detail">siRNA - Novartis</div>
                            <div class="competitor-detail">Twice-yearly dosing advantage</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Oral PCSK9i</div>
                            <div class="competitor-detail">Merck (Phase 3)</div>
                            <div class="competitor-detail">Convenience of oral dosing</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Lerodalcibep</div>
                            <div class="competitor-detail">LIB Therapeutics</div>
                            <div class="competitor-detail">Monthly dosing, Phase 3</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Future Outlook</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Patent Expiry & Biosimilars</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>US Market:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Exclusivity ends late 2027</li>
                                        <li>Biosimilars possible from 2028</li>
                                        <li>Expected 30-50% price reduction</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>EU Market:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Similar timeline to US</li>
                                        <li>Earlier entries if patents challenged</li>
                                        <li>Pricing pressures from inclisiran deals</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: rgba(102, 126, 234, 0.1); border-radius: 8px;">
                                <strong>Strategic Position:</strong> Despite competition from newer agents, Repatha's extensive outcomes data (FOURIER) and established safety profile ensure continued relevance. Biosimilar competition may actually improve access by reducing costs.
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tab contents
            const tabContents = document.querySelectorAll('.tab-content');
            tabContents.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected tab content
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }

        // Animate bars on first view
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growBar 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        });

        const chartContainers = document.querySelectorAll('.efficacy-bar-chart');
        chartContainers.forEach(container => {
            observer.observe(container);
        });

        // Add animation keyframe
        const style = document.createElement('style');
        style.textContent = `
            @keyframes growBar {
                from { transform: scaleY(0); }
                to { transform: scaleY(1); }
            }
        `;
        document.head.appendChild(style);
    </script>
</body>
</html>